Escitalopram (Lexapro)

Generics already compete: 14 makers on the market. 41 A-rated products from 14 makers substitute at the counter.

Lexapro was first approved by the FDA on 08/14/2002 under NDA 021323; the application holder is Abbvie Inc.

The latest NADAC for ESCITALOPRAM 5 MG TABLET is $0.04 per unit (as of 10/28/2026).

Holder Abbvie IncApplication NDA 021323Approved 08/14/2002

Open full profile Start free trial

Data as of 10/30/2026

Market protectionExpiredExclusivity ends 05/12/2026 Generics14 makersPriced in NADAC FDA shortageClearNot listedCurrent FDA list NADAC$0.04 / unitMid-priced of 3 strengths

01Patents and exclusivity

When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.

Latest listed protection expired 05/12/2026

ExclusivityPatent onlyOpen to generics

Today

Approved08/14/2002

Exclusivity ends05/12/2026

2003200720112015201920232027

Latest patent: No Lexapro patent listed in the Orange Book
Exclusivity: 05/12/2026Lexapro

02Competition

Generics: 14 generic makers
First generic approved: 07/31/2007

Every listingEach listing and maker behind the generics count.

Price erosionHow NADAC moves as generics enter.

PrescribersWho prescribes it, from Medicare data.

Available in the full Escitalopram profile.See what is included

03Supply and price

FDA drug shortage: ClearNot on the current shortage list
NADAC: $0.04 per unitESCITALOPRAM 5 MG TABLET, mid-priced of 3 strengths, as of 10/28/2026

04Product

Application holder: Abbvie Inc
Application: NDA 021323
First approved: 08/14/2002
Dosage forms: capsule; solution; tablet
Routes: oral

Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.